These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37363833)

  • 1. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
    van der Straten L; Stege CAM; Kersting S; Nasserinejad K; Dubois J; Dobber JA; Mellink CHM; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken JH; Levenga H; Tick LW; Terpstra WE; Tonino SH; Westerweel PE; Langerak AW; Kater AP; Levin MD
    Blood; 2023 Sep; 142(13):1131-1142. PubMed ID: 37363833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
    Kersting S; Dubois J; Nasserinejad K; Dobber JA; Mellink C; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken H; Levenga H; Tick LW; Terpstra WE; Tonino SH; Boyer M; Mobasher M; Levin MD; Kater AP;
    Lancet Haematol; 2022 Mar; 9(3):e190-e199. PubMed ID: 35240075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Al-Sawaf O; Gentile B; Devine J; Zhang C; Sail K; Tandon M; Fink AM; Kutsch N; Wendtner CM; Eichhorst B; Hallek M; Fischer K
    Am J Hematol; 2021 Sep; 96(9):1112-1119. PubMed ID: 34050972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
    N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
    Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
    Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
    Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
    Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
    Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
    Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
    Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
    Cho SK; Manzoor BS; Sail KR; Parisé H; Ravelo A; Shapouri S; Kapustyan T; Sharmokh S; Virabhak S; Davids MS; Johnson S
    Pharmacoeconomics; 2020 Sep; 38(9):941-951. PubMed ID: 32383129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
    Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
    J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
    Al-Sawaf O; Robrecht S; Zhang C; Olivieri S; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Sivchev L; Niemann CU; Schwarer A; Loscertales J; Weinkove R; Strumberg D; Kilfoyle A; Manzoor BS; Jawaid D; Emechebe N; Devine J; Boyer M; Runkel ED; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    Blood; 2024 Oct; 144(18):1924-1935. PubMed ID: 39082668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
    N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
    N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
    J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.